E. Piazza

1.7k total citations
42 papers, 663 citations indexed

About

E. Piazza is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, E. Piazza has authored 42 papers receiving a total of 663 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in E. Piazza's work include Cancer Treatment and Pharmacology (12 papers), Colorectal Cancer Treatments and Studies (7 papers) and Lung Cancer Treatments and Mutations (6 papers). E. Piazza is often cited by papers focused on Cancer Treatment and Pharmacology (12 papers), Colorectal Cancer Treatments and Studies (7 papers) and Lung Cancer Treatments and Mutations (6 papers). E. Piazza collaborates with scholars based in Italy, Malaysia and Philippines. E. Piazza's co-authors include L. Frontini, Ciro Gallo, Giovanni Pietro Ianniello, Cesare Gridelli, Sergio Robbiati, Michela Pisoni, Maurizio D’Incalci, Maria Teresa Rocchetti, Margaret S. Beer and G Masera and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

E. Piazza

39 papers receiving 629 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E. Piazza Italy 15 381 147 140 99 85 42 663
Mark J. O’Connor United Kingdom 14 300 0.8× 143 1.0× 231 1.6× 83 0.8× 113 1.3× 35 825
M. Soukop United Kingdom 18 314 0.8× 147 1.0× 113 0.8× 91 0.9× 318 3.7× 53 858
Danielle Awad United States 11 829 2.2× 136 0.9× 155 1.1× 68 0.7× 60 0.7× 22 1.2k
Samuela Carraro Italy 11 212 0.6× 93 0.6× 106 0.8× 29 0.3× 61 0.7× 31 678
Lois Brafman United States 11 832 2.2× 159 1.1× 88 0.6× 32 0.3× 76 0.9× 22 1.2k
J. A. Russell United States 7 102 0.3× 86 0.6× 195 1.4× 37 0.4× 91 1.1× 8 874
Krzysztof Krzemieniecki Poland 14 412 1.1× 253 1.7× 130 0.9× 101 1.0× 99 1.2× 58 801
Daniela Rizzo Italy 17 102 0.3× 130 0.9× 182 1.3× 66 0.7× 113 1.3× 37 705
Shelby A. Terstriep United States 8 836 2.2× 153 1.0× 87 0.6× 16 0.2× 107 1.3× 17 1.2k
S Purl United States 7 337 0.9× 148 1.0× 219 1.6× 45 0.5× 52 0.6× 8 757

Countries citing papers authored by E. Piazza

Since Specialization
Citations

This map shows the geographic impact of E. Piazza's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Piazza with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Piazza more than expected).

Fields of papers citing papers by E. Piazza

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Piazza. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Piazza. The network helps show where E. Piazza may publish in the future.

Co-authorship network of co-authors of E. Piazza

This figure shows the co-authorship network connecting the top 25 collaborators of E. Piazza. A scholar is included among the top collaborators of E. Piazza based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Piazza. E. Piazza is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
2.
Belletti, Alessandro, E. Piazza, Gianluca Paternoster, et al.. (2024). Extracorporeal membrane oxygenation for prevention of barotrauma in patients with respiratory failure: A scoping review. Artificial Organs. 49(2). 183–195. 4 indexed citations
4.
Giorgis, Valentina De, Costanza Varesio, Cristina Baldassari, et al.. (2016). Atypical Manifestations in Glut1 Deficiency Syndrome. Journal of Child Neurology. 31(9). 1174–1180. 29 indexed citations
5.
6.
Battisti, Emilio, Alberto Albanese, Laura Bianciardi, et al.. (2007). Efficacy and safety of new TAMMEF (therapeutic application of musically modulated electromagnetic fields) system in the treatment of chronic low back pain. The Environmentalist. 27(4). 441–445. 1 indexed citations
7.
Maio, Marco Di, Ciro Gallo, A. Ceribelli, et al.. (2006). Two-drug gemcitabine-based first-line treatment of elderly patients (pts) with small cell lung cancer (SCLC): The G-STEP program. Journal of Clinical Oncology. 24(18_suppl). 7089–7089. 2 indexed citations
8.
Cantore, Maurizio, G. Fiorentini, Gabriele Luppi, et al.. (2004). Ceravolo. Journal of Chemotherapy. 16(6). 589–594. 21 indexed citations
9.
Barni, Sandro, E. Piazza, L. Frontini, et al.. (2004). Single-Agent Epirubicin as Primary Chemotherapy in T2–T3, N0–N2, M0 Breast Carcinoma: 6-Year Follow-Up. Oncology. 67(1). 40–47. 5 indexed citations
10.
Maïo, Massimo Di, Federica Perrone, Ciro Gallo, et al.. (2003). Supportive care in patients with advanced non-small-cell lung cancer. British Journal of Cancer. 89(6). 1013–1021. 19 indexed citations
11.
Sobrero, Alberto, Alberto Zaniboni, Giovanni Luca Frassineti, et al.. (2000). Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: A randomized study. Annals of Oncology. 11(11). 1413–1420. 15 indexed citations
12.
Gridelli, Cesare, L. Frontini, Federica Perrone, et al.. (2000). Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses. British Journal of Cancer. 83(6). 707–714. 51 indexed citations
13.
Cascinu, Stefano, Sandro Barni, Roberto Labianca, et al.. (1999). A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). British Journal of Cancer. 80(10). 1595–1598. 68 indexed citations
14.
Labianca, Roberto, Stefano Cascinu, L. Frontini, et al.. (1997). High- versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: A ‘GISCAD’ phase III study. Annals of Oncology. 8(2). 169–174. 20 indexed citations
15.
Piazza, E., et al.. (1997). 138 Gemcitabine in the treatment of pretreated metastatic non small cell lung cancer: A preliminary report. Lung Cancer. 18. 38–38. 2 indexed citations
16.
Gaudio, Angelo Raffaele De, et al.. (1995). Peri‐operative assessment of glomerular permeability. Anaesthesia. 50(9). 810–812. 5 indexed citations
17.
Labianca, Roberto, Sandro Barni, G. Ambrosini, et al.. (1994). Double modulation of 5-fluorouracil in advanced colorectal cancer with low-dose interferon-α2b and folinic acid. The “GISCAD” experience. European Journal of Cancer. 30(11). 1611–1616. 8 indexed citations
18.
Cattaneo, Marco, et al.. (1988). Transient blindness and seizure associated with cisplantin therapy. Journal of Cancer Research and Clinical Oncology. 114(5). 528–530. 22 indexed citations
19.
Gaudemaris, R. De, et al.. (1986). [Analysis of the risk of backache in the occupational environment].. PubMed. 34(4-5). 308–17. 13 indexed citations
20.
Morasca, L., Silvia Marsoni, E. Piazza, et al.. (1980). Plasma levels of cyclophosphamide in patients under polychemotherapeutic regimens.. PubMed. 32(3). 123–7. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026